Factor V Deficiency.
Stoj KM, Pierro J.
2024 May 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–.
Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis.
Hirani N, MacKinnon AC, Nicol L, Ford P, Schambye H, Pedersen A, Nilsson UJ, Leffler H, Sethi T, Tantawi S, Gravelle L, Slack RJ, Mills R, Karmakar U, Humphries D, Zetterberg F, Keeling L, Paul L, Molyneaux PL, Li F, Funston W, Forrest IA, Simpson AJ, Gibbons MA, Maher TM.
Eur Respir J. 2021 May 27;57(5):2002559. doi: 10.1183/13993003.02559-2020. Print 2021 May.
Clinical Pharmacokinetics and Pharmacodynamics of Desmoteplase.
Piechowski-Jozwiak B, Abidi E, El Nekidy WS, Bogousslavsky J.
Eur J Drug Metab Pharmacokinet. 2022 Mar;47(2):165-176. doi: 10.1007/s13318-021-00743-8. Epub 2021 Dec 11.
Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial.
Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators; Van De Werf F, Adgey J, Ardissino D, Armstrong PW, Aylward P, Barbash G, Betriu A, Binbrek AS, Califf R, Diaz R, Fanebust R, Fox K, Granger C, Heikkilä J, Husted S, Jansky P, Langer A, Lupi E, Maseri A, Meyer J, Mlczoch J, Mocceti D, Myburgh D, Oto A, Paolasso E, Pehrsson K, Seabra-Gomes R, Soares-Piegas L, Sùgrue D, Tendera M, Topol E, Toutouzas P, Vahanian A, Verheugt F, Wallentin L, White H.
Lancet. 1999 Aug 28;354(9180):716-22. doi: 10.1016/s0140-6736(99)07403-6.
Development of a plasminogen activator inhibitor (PAI-1) assay and comparison of plasma PAI-1 activity in hyperlipidemic/dyslipidemic dogs with either hyperadrenocorticism or diabetes mellitus, and healthy dogs.
Wong CJ, Koch M, Behling-Kelly EL.
Res Vet Sci. 2017 Apr;111:1-8. doi: 10.1016/j.rvsc.2016.11.004. Epub 2016 Nov 8.
Mannose-binding lectin-associated serine protease-1 cleaves plasminogen and plasma fibronectin: prefers plasminogen over known fibrinogen substrate.
Choudhary K, Patel PK, Are VN, Makde RD, Hajela K.
Blood Coagul Fibrinolysis. 2021 Oct 1;32(7):504-512. doi: 10.1097/MBC.0000000000001074.
Dyslipidemias and fibrinolysis.
Puccetti L, Bruni F, Pasqui AL, Pastorelli M, Bova G, Cercignani M, Palazzuoli A, Auteri A.
Ital Heart J. 2002 Oct;3(10):579-86.
Design of a DNA-Programmed Plasminogen Activator.
Mukherjee P, Leman LJ, Griffin JH, Ghadiri MR.
J Am Chem Soc. 2018 Nov 14;140(45):15516-15524. doi: 10.1021/jacs.8b10166. Epub 2018 Nov 1.
Cutaneous and plasma fibrinolytic activity in systemic sclerosis. Evidence of normal plasminogen activation.
Matucci-Cerinic M, Lotti T, Lombardi A, Pignone A, Iannone F, Beneforti E, Cinotti S, Morfini M, Caignoni M.
Int J Dermatol. 1990 Nov;29(9):644-8. doi: 10.1111/j.1365-4362.1990.tb02587.x.
Measuring fibrinolysis: from research to routine diagnostic assays.
Longstaff C.
J Thromb Haemost. 2018 Apr;16(4):652-662. doi: 10.1111/jth.13957. Epub 2018 Feb 17.
